Bharat Biotech, Biofabri Partner for TB Vaccine Deal

• Biofabri and Bharat Biotech sign an agreement to develop the MTBVAC TB vaccine for high-burden regions
• MTBVAC has shown safety and immune response in Phase I and II trials; Phase III study begins in 2026
• MTBVAC aims to support India’s TB Mukt Bharat initiative and global TB eradication efforts

Bharat Biotech, a vaccine supplier from Hyderabad, has signed a technology-transferring contract with Biofabri, a worldwide authority in the development of human vaccines, to continue developing a revolutionary TB vaccine candidate.

This collaboration will allow for greater access to TB vaccinations according to WHO goals and aspirations in high-burden areas such as Africa and Southeast Asia. Bharat Biotech has committed to the creation and supply of MTBVAC a new TB vaccine candidate in more than 70 countries throughout the globe per the agreement.

The Phase I and II clinical trials conducted in India of MTBVAC have shown that it is safe and elicits strong immune responses.

Also Read: GAIL, Chhattisgarh Govt Sign Pact for Gas-Based Fertilizer Plant

Now, with these encouraging data trends, Bharat Biotech will be commencing a large scale Phase III study measuring the efficacy of MTBVAC; plans include recruitment of volunteers for this trial to start in the first quarter of 2026.

Bharat Biotech also stated that because of the enormous burden of TB in India, it is anticipated that MTBVAC will play a strategic role in supporting the goal of Prime Minister Modi’s TB Mukt Bharat campaign, which is the elimination of tuberculosis from the Indian subcontinent.

This announcement highlights a positive step forward in the global effort to combat tuberculosis and promote the availability of vaccines that can be life-saving.